Intensifying Competition in Weight Loss Drug Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 08 2026
0mins
Should l Buy NVO?
Source: Yahoo Finance
- Novo Nordisk's Market Leadership: Novo Nordisk's GLP-1 drug Wegovy has become a best-seller in the weight loss sector, and its newly launched oral version is expected to further expand market share, driving company growth in the coming years.
- New Drug Development Progress: Novo Nordisk's CagriSema has outperformed Wegovy in clinical studies and is under consideration for approval, while amycretin in phase 3 studies and UBT251 showing strong efficacy in mid-stage trials in China further enrich its weight loss drug portfolio.
- Amgen's Potential Advantage: Although Amgen has yet to gain approval for a weight loss drug, its candidate MariTide is in phase 3 studies and could receive approval within three years, with its monthly dosing regimen potentially providing a competitive edge.
- Investment Risk Assessment: While Novo Nordisk has a stronger portfolio of weight loss products, it has lost market share to competitor Eli Lilly, making Amgen's diversified product lineup a potentially safer investment choice with lower entry risks in the weight loss market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 44.740
Low
42.00
Averages
54.67
High
70.00
Current: 44.740
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intensifying Competition in Weight Loss Drug Market
- Market Leaders: Eli Lilly and Novo Nordisk dominate the weight loss drug market, with recent launches like Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo further attracting new patients and solidifying their market share.
- Drug Advantages: Oral weight loss medications are favored for their convenience and ease of management, particularly for patients who travel frequently, indicating that the market potential remains underdeveloped and is expected to drive growth in this sector.
- Viking Therapeutics' Challenges: Viking Therapeutics' VK2735 demonstrated a weight loss of up to 12.2% in clinical trials, but safety concerns arose as 38% of patients discontinued treatment due to side effects, necessitating resolution in future studies.
- Investment Risks and Opportunities: Despite facing intense competition and challenges related to profitability, Viking Therapeutics could offer significant returns for investors if it achieves positive results in upcoming clinical trials.
See More
Eli Lilly's Stock Volatility and Future Outlook
- Stock Volatility Analysis: Eli Lilly's shares trended downward until late April, dropping below $900, but surged past $1,000 following the first-quarter earnings report, indicating strong market confidence in its future growth.
- Increased Competitive Pressure: While Eli Lilly dominates the anti-obesity market, competitors like Novo Nordisk are launching next-generation weight-loss drugs, which could pressure Eli Lilly's market share and pricing power in the coming years.
- R&D Investment Outlook: Strong sales growth in oncology, immunology, and neuroscience, bolstered by strategic acquisitions, is expected to drive Eli Lilly's stock price higher over the next few years, further solidifying its market leadership.
- AI Application Potential: Eli Lilly is exploring the use of artificial intelligence to enhance drug development, having built the industry's most powerful supercomputer, which could shorten drug discovery timelines by 1-2 years, significantly reducing R&D costs and boosting profit margins.
See More
Trump Administration Expands Drug Sales Platform
- Platform Expansion: The Trump administration announced the addition of over 600 generic medications to the TrumpRx platform, aiming to lower prescription drug costs in the U.S. by providing consumers with easier access to affordable medications.
- New Tools Launched: The platform now features tools that connect patients with the lowest-priced pharmacies nearby and offers home delivery options for prescriptions, enhancing user experience and potentially attracting more consumers to the platform.
- Partnerships Established: The administration is partnering with industry players like Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to promote transparent pricing, further strengthening the platform's competitive position in the market.
- User Traffic: Since its launch, TrumpRx has garnered over 10 million visits and saved Americans more than $400 million, although it remains unclear if all patients will achieve greater cost savings compared to existing purchasing methods.
See More
Trump Administration Expands TrumpRx with Generic Medications
- Platform Expansion: The Trump administration announced the addition of over 600 generic medications to the TrumpRx website, aiming to lower prescription drug costs in the U.S. by providing transparent pricing and enhancing consumer choice.
- New Tools Launched: The platform now features tools that connect patients with the lowest-priced pharmacies in their area and offers home delivery options for prescriptions, improving user experience and facilitating easier access to medications.
- Partnerships Established: The administration is partnering with industry players like Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to promote direct-to-consumer drug sales, ensuring price transparency for consumers.
- User Engagement and Savings: Since its launch, TrumpRx has recorded over 10 million visits and saved Americans more than $400 million, although it remains unclear if all patients will benefit from this platform compared to traditional purchasing methods.
See More
Pharmaceutical Giants' Acquisition Targets Analysis
- Viking Therapeutics Highlights: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, has enrolled over 4,500 patients in Phase 3 ahead of schedule, with oral formulations achieving a 12.2% body weight reduction in 13 weeks, making it a strategically attractive acquisition target with a market cap of $3.69 billion and $706 million in cash.
- Scholar Rock's Market Potential: Scholar Rock's muscle-targeted therapy apitegromab is expected to launch in Europe in H2 2026, already partnered with Novo Nordisk, with a market cap of $5.55 billion and an analyst target price of $57.73, highlighting its significance in the GLP-1 landscape.
- Verve Therapeutics' Outlook: Verve Therapeutics' VERVE-102, a single-dose gene-editing PCSK9 therapy, achieved a 53% mean LDL-C reduction in the Heart-2 Phase 1b trial, with Lilly holding an opt-in that may lead to outright acquisition, showcasing its potential in cardiovascular disease treatment.
- Market Competition Dynamics: Eli Lilly and Novo Nordisk are aggressively acquiring early-stage therapeutics to maintain GLP-1 market dominance, with Lilly's recent four acquisitions indicating its expansion strategy, despite Novo facing pricing pressures and declining sales challenges.
See More
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
Intensifying Competition in Weight Loss Drug Market
- Market Leaders: Eli Lilly and Novo Nordisk dominate the weight loss drug market, with recent launches like Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo further attracting new patients and solidifying their market share.
- Drug Advantages: Oral weight loss medications are favored for their convenience and ease of management, particularly for patients who travel frequently, indicating that the market potential remains underdeveloped and is expected to drive growth in this sector.
- Viking Therapeutics' Challenges: Viking Therapeutics' VK2735 demonstrated a weight loss of up to 12.2% in clinical trials, but safety concerns arose as 38% of patients discontinued treatment due to side effects, necessitating resolution in future studies.
- Investment Risks and Opportunities: Despite facing intense competition and challenges related to profitability, Viking Therapeutics could offer significant returns for investors if it achieves positive results in upcoming clinical trials.
See More
Eli Lilly's Stock Volatility and Future Outlook
- Stock Volatility Analysis: Eli Lilly's shares trended downward until late April, dropping below $900, but surged past $1,000 following the first-quarter earnings report, indicating strong market confidence in its future growth.
- Increased Competitive Pressure: While Eli Lilly dominates the anti-obesity market, competitors like Novo Nordisk are launching next-generation weight-loss drugs, which could pressure Eli Lilly's market share and pricing power in the coming years.
- R&D Investment Outlook: Strong sales growth in oncology, immunology, and neuroscience, bolstered by strategic acquisitions, is expected to drive Eli Lilly's stock price higher over the next few years, further solidifying its market leadership.
- AI Application Potential: Eli Lilly is exploring the use of artificial intelligence to enhance drug development, having built the industry's most powerful supercomputer, which could shorten drug discovery timelines by 1-2 years, significantly reducing R&D costs and boosting profit margins.
See More
Trump Administration Expands Drug Sales Platform
- Platform Expansion: The Trump administration announced the addition of over 600 generic medications to the TrumpRx platform, aiming to lower prescription drug costs in the U.S. by providing consumers with easier access to affordable medications.
- New Tools Launched: The platform now features tools that connect patients with the lowest-priced pharmacies nearby and offers home delivery options for prescriptions, enhancing user experience and potentially attracting more consumers to the platform.
- Partnerships Established: The administration is partnering with industry players like Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to promote transparent pricing, further strengthening the platform's competitive position in the market.
- User Traffic: Since its launch, TrumpRx has garnered over 10 million visits and saved Americans more than $400 million, although it remains unclear if all patients will achieve greater cost savings compared to existing purchasing methods.
See More
Trump Administration Expands TrumpRx with Generic Medications
- Platform Expansion: The Trump administration announced the addition of over 600 generic medications to the TrumpRx website, aiming to lower prescription drug costs in the U.S. by providing transparent pricing and enhancing consumer choice.
- New Tools Launched: The platform now features tools that connect patients with the lowest-priced pharmacies in their area and offers home delivery options for prescriptions, improving user experience and facilitating easier access to medications.
- Partnerships Established: The administration is partnering with industry players like Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to promote direct-to-consumer drug sales, ensuring price transparency for consumers.
- User Engagement and Savings: Since its launch, TrumpRx has recorded over 10 million visits and saved Americans more than $400 million, although it remains unclear if all patients will benefit from this platform compared to traditional purchasing methods.
See More
Pharmaceutical Giants' Acquisition Targets Analysis
- Viking Therapeutics Highlights: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, has enrolled over 4,500 patients in Phase 3 ahead of schedule, with oral formulations achieving a 12.2% body weight reduction in 13 weeks, making it a strategically attractive acquisition target with a market cap of $3.69 billion and $706 million in cash.
- Scholar Rock's Market Potential: Scholar Rock's muscle-targeted therapy apitegromab is expected to launch in Europe in H2 2026, already partnered with Novo Nordisk, with a market cap of $5.55 billion and an analyst target price of $57.73, highlighting its significance in the GLP-1 landscape.
- Verve Therapeutics' Outlook: Verve Therapeutics' VERVE-102, a single-dose gene-editing PCSK9 therapy, achieved a 53% mean LDL-C reduction in the Heart-2 Phase 1b trial, with Lilly holding an opt-in that may lead to outright acquisition, showcasing its potential in cardiovascular disease treatment.
- Market Competition Dynamics: Eli Lilly and Novo Nordisk are aggressively acquiring early-stage therapeutics to maintain GLP-1 market dominance, with Lilly's recent four acquisitions indicating its expansion strategy, despite Novo facing pricing pressures and declining sales challenges.
See More
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
